NAAG peptidase inhibition reduces locomotor activity and some stereotypes in the PCP model of schizophrenia via group II mGluR

Journal of Neurochemistry

Volumn 89, Issue 4, 2004, Pages 876-885

  Olszewski, Rafal T ^a,b   Bukhari, Noreen ^a   Zhou, Jia ^a   Kozikowski, Alan P ^a,c   Wroblewski, Jarda T ^a   Shamimi Noori, Susan ^a   Wroblewska, Barbara ^a   Bzdega, Tomasz ^a   Vicini, Stefano ^a   Barton, Franca B ^a   Neale, Joseph H ^a  

^a GEORGETOWN UNIVERSITY   (United States)

^b INSTITUTE OF GENETICS AND ANIMAL BREEDING   (Poland)

^c UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

mGluR3; N acetylaspartylglutamate; NMDA receptors; Phencyclidine; Schizophrenia

Indexed keywords

2 AMINO 2 (2 CARBOXYCYCLOPROPYL) 3 (XANTHEN 9 YL)PROPIONIC ACID; ENZYME INHIBITOR; GLUTAMATE DECARBOXYLASE; GLUTAMATE DECARBOXYLASE 2; GLUTAMATE DECARBOXYLASE 3; METABOTROPIC RECEPTOR 2; METABOTROPIC RECEPTOR AGONIST; METABOTROPIC RECEPTOR ANTAGONIST; N ACETYLASPARTYLGLUTAMIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; NEUROTRANSMITTER; PEPTIDE; PHENCYCLIDINE; UNCLASSIFIED DRUG; UREA; ZJ43; DRUG DERIVATIVE; GLUTAMATE CARBOXYPEPTIDASE II; METABOTROPIC RECEPTOR;

ANIMAL BEHAVIOR; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CIRCLING BEHAVIOR; CONTROLLED STUDY; DRUG EFFECT; DRUG MECHANISM; DRUG POTENCY; DRUG RECEPTOR BINDING; ENZYME INACTIVATION; ENZYME INHIBITION; EXPERIMENTAL MODEL; EXTRACELLULAR SPACE; FALLING; HEAD MOVEMENT; LOCOMOTION; MALE; MOTOR ACTIVITY; NEUROCHEMISTRY; NEUROTRANSMITTER RELEASE; NONHUMAN; PEPTIDE ANALYSIS; PEPTIDE SYNTHESIS; PRIORITY JOURNAL; PROTEIN INDUCTION; RAT; REGULATORY MECHANISM; SCHIZOPHRENIA; STEREOTYPY; SYMPTOM; SYNAPTIC TRANSMISSION; WALKING; ANIMAL; CELL CULTURE; CHEMICALLY INDUCED DISORDER; DISEASE MODEL; DRUG ANTAGONISM; METABOLISM; SPRAGUE DAWLEY RAT; SYNTHESIS;

ANIMALIA;

ANIMALS; BEHAVIOR, ANIMAL; CELLS, CULTURED; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; GLUTAMATE CARBOXYPEPTIDASE II; MALE; MOTOR ACTIVITY; PHENCYCLIDINE; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, METABOTROPIC GLUTAMATE; SCHIZOPHRENIA; STEREOTYPED BEHAVIOR; UREA;

EID: 19244371242     PISSN: 00223042     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1471-4159.2004.02358.x     Document Type: Article

References (50)

1. Bacich D. J., Ramadan E., O'Keefe D. S., Bukhari N., Wegorzewska I., Ojeifo O., Olszewski R., Wrenn C. C., Bzdega T., Wroblewska B., Heston W. D. and Neale J. H. (2002) Deletion of the glutamate carboxypeptidase II gene in mice reveals a second enzyme activity that hydrolyzes N-acetylaspartylglutamate. J. Neurochem. 83, 20-29.
2. Bruno V., Wroblewska B., Wroblewski J. T., Fiore L. and Nicoletti F. (1998) Neuroprotective activity of N-acetylaspartylglutamate in cultured cortical cells. Neuroscience 85, 751-757.
3. Bzdega T., Crowe S. L., Ramadan E., Sciarretta K., Olszewski R. T., Ojeifo O., Rafalski V. A., Wroblewska B. and Neale J. H. (2004) Cloning and characterization of a second enzyme with NAAG peptidase activity. J. Neurochem. 2004 (in press).
4. Carlsson A. (1988) The current status of the dopamine hypothesis of schizophrenia. Neuropsychopharmacology 1, 179-186.
5. Cartmell J., Monn J. A. and Schoepp D. D. (1999) The metabotropic glutamate 2/3 receptor agonists LY354740 and LY379268 selectively attenuate phencyclidine versus d-amphetamine motor behaviors in rats. J. Pharmacol. Exp Ther. 291, 161-170.
6. Cartmell J., Monn J. A. and Schoepp D. D. (2000) Tolerance to the motor impairment, but not to the reversal of PCP-induced motor activities by oral administration of the mGlu2/3 receptor agonist, LY379268. Naunyn Schmiedebergs Arch. Pharmacol. 361, 39-46.
7. 2 receptor-transfected cell membranes. Br. J. Pharmacol. 123, 497-504.
8. Chen C. and Okayama H. (1987) High-efficiency transformation of mammalian cells by plasmid DNA. Mol. Cell Biol. 7, 2745-2752.
9. Cheng Y. and Prusoff W. H. (1973) Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 percent inhibition (I50) of an enzymatic reaction. Biochem. Pharmacol. 22, 3099-3108.
10. Flores C. and Coyle J. T. (2003) Regulation of glutamate carboxypeptidase II function in corticolimbic regions of rat brain by phencycldine, haloperidol and clozapine. Neuropsychopharmacology 28, 1227-1234.
11. Fuhrman S., Neale J. H., Cassidy M. and Palkovits M. (1994) The regional distribution of N-acetylaspartylglutamate (NAAG) and peptidase activity against NAAG in the rat nervous system. J. Neurochem. 62, 275-281.
12. Gallo V., Kingsbury A., Balazs R. and Jorgensen O. S. (1987) The role of depolarization in the survival and differentiation of cerebellar granule cells in culture. J. Neurosci. 7, 2203-2213.
13. Garrido Sanabria E. R., Wozniak K. M., Slusher B. S. and Keller A. (2004) GCP II (NAALADase) inhibition suppresses mossy fiber-CA3 synaptic neurotransmission by a presynaptic mechanism. J. Neurophysiol. 91, 182-193.
14. Ghadge G. D., Slusher B. S., Bodner A. et al. (2003) Glutamate carboxypeptidase II inhibition protects motor neurons from death in familial amyotrophic lateral sclerosis models. Proc. Natl Acad. Sci. USA 100, 9554-95549.
15. Ghose S., Wroblewska B., Corsi L., Grayson D. R., De Blas A. L., Vicini S. and Neale J. H. (1997) N-Acetylaspartylglutamate stimulates metabotropic glutamate receptor 3 to regulate expression of the GABA (A) alpha6 subunit in cerebellar granule cells. J. Neurochem. 69, 2326-2335.
16. Greene R. (2001) Circuit analysis of NMDAR hypofunction in the hippocampus, in vitro, and psychosis of schizophrenia. Hippocampus 1, 569-577.
17. Javitt D. C. and Zukin S. R. (1991) Recent advances in the phencyclidine model of schizophrenia. Am. J. Psychiatry 148, 1301-1308.
18. Kelley A. E. and Delfs J. M. (1994) Excitatory amino acid receptors mediate the orofacial stereotypy elicited by dopaminergic stimulation of the ventrolateral striatum. Neuroscience 60, 85-95.
19. Kozikowski A. P., Nan F., Conti P., Zhang J., Ramadan E., Bzdega T., Wroblewska B., Neale J. H., Pshenichkin S. and Wroblewski J. T. (2001) Design of remarkably simple, yet potent urea-based inhibitors of glutamate carboxypeptidase II (NAALADase). J. Med. Chem. 44, 298-301.
20. Kozikowski A. P., Zhang J., Nan F., Petukhov P., Grajkowska E., Wroblewski J. T., Yamamoto T., Bzdega T., Wroblewska B. and Neale J. H. (2003) Synthesis of urea-based inhibitors as active site probes of glutamate carboxypeptidase I: efficacy as analgesic agents. J. Med. Chem. (in press).
21. Krystal J. H., Karper L. P., Seibyl J. P., Freeman G. K., Delaney R., Bremner J. D., Heninger G. R., Bowers M. B. J. and Charney D. S. (1994) Subanesthetic effects of the noncompetitive NMDA antagonist, ketamine, in humans: psychotomimetic, perceptual, cognitive, and neuroendocrine responses. Arch. Gen. Psychiatry 51, 199-214.
22. Krystal J. H., D'Souza D. C., Petrakis I. L., Belger A., Berman R. M., Charney D. S., Abi-Saab W. and Madonick S. (1999) NMDA agonists and antagonists as probes of glutamatergic dysfunction and pharmacotherapies in neuropsychiatric disorders. Harv. Rev. Psychiatry 7, 125-143.
23. Lea P. M., Wroblewska B., 4th, Sarvey J. M. and Neale J. H. (2001) beta-NAAG rescues LTP from blockade by NAAG in rat dentate gyrus via the type 3 metabotropic glutamate receptor. J. Neurophysiol. 85, 1097-1106.
24. Lewis D. A. and Lieberman J. A. (2000) Catching up on schizophrenia: natural history and neurobiology. Neuron 28, 325-334.
25. Losi G. Vicini S. and Neale J. (2003) NAAG fails to antagonize synaptic and extrasynaptic NMDA receptors in cerebellar granule neurons. Neuropharmacology 46, 490-496.
26. Losi G. Prybylowski K. Fu Z. Luo J. H. and Vicini S. (2002) Evidence of silent synapses in cerebellar granule cells. J. Neurophysiol. 87, 1263-1270.
27. Moghaddam B. and Adams B. W. (1998) Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. Science 281, 1349-1352.
28. Mohn A. R. Gainetdinov R. R. Caron M. G. and Koller B. H. (1999) Mice with reduced NMDA receptor expression display behaviors related to schizophrenia. Cell 98, 427-436.
29. Nan F. Bzdega T. Pshenichkin S. Wroblewski J. T. Wroblewska B. Neale J. H. and Kozikowski A. P. (2000) Dual function glutamate-related ligands: discovery of a novel, potent inhibitor of glutamate carboxypeptidase II possessing mGluR3 agonist activity. J. Med. Chem. 43, 772-774.
30. Neale J. H. Bzdega T. and Wroblewska B. (2000) N-Acetylaspartylglutamate: the most abundant peptide neurotransmitter in the mammalian central nervous system. J. Neurochem. 75, 443-452.
31. Nudmamud S. Reynolds L. M. and Reynolds G. P. (2003) N-Acetylaspartate and N-acetylaspartylglutamate deficits in superior temporal cortex of schizophrenia and bipolar disorder: a postmortem study. Biol. Psychiatry 53, 1138-1141.
32. O'Neill M. F. Heron-Maxwell C. Conway M. W. Monn J. A. and Ornsetein P. (2003) Group II metabotropic glutamate receptor antagonists LY 341495 and LY366457 increase locomotor activity in mice. Neuropharmacology 45, 565-574.
33. Ohishi H. Ogawameguro R. Shigemoto R. Kaneko T. Nakanishi S. and Mizuno N. (1994) Immunohistochemical localization of metabotropic glutamate receptors, mGluR2 and mGluR3, in rat cerebellar cortex. Neuron 13, 55-66.
34. Pin J. P. and Acher F. (2002) The metabotropic glutamate receptors: structure, activation mechanism and pharmacology. Curr. Drug Target CNS Neurol. Disord. 1, 297-317.
35. Prybylowski K. L. Fu Z. Losi G. Hawkins L. M. Luo J. H. Chang K. Whenthold R. J. and Vicini S. (2002) Relationship between availability of NMDA receptor subunits and their expression at the synapse. J. Neurosci. 22, 8902-8910.
36. Pulver A. E. Mulle J. Nestadt G. et al. (2000) Genetic heterogeneity in schizophrenia: stratification of genome scan data using co-segregating related phenotypes. Mol. Psychiatry 5, 650-653.
37. Riveros N. and Orrego F. (1984) A study of possible excitatory effects of N-acetylaspartylglutamate in different in vivo and in vitro brain preparations. Brain Res. 299, 393-395.
38. Robinson M. B., Blakely R. D., Couto R. and Coyle J. T. (1987) Hydrolysis of the brain dipeptide N-acetyl-L-aspartyl-L-glutamate. Identification and characterization of a novel N-acetylated alpha-linked acidic dipeptidase activity from rat brain. J. Biol. Chem. 262, 14498-14506.
39. Schweitzer C., Kratzeisen C., Adam G., Lundstrom K., Malherbe P., Ohresser S., Stadler H., Wichmann J., Woltering T. and Mutel V. (2000) Characterization of-LY354740 binding to rat mGlu2 and mGlu3 receptors expressed in CHO cells using Semliki Forest virus vectors. Neuropharmacology 39, 1700-1706.
40. Slusher B. S., Vornov J. J., Thomas A. G. et al. (1999) Selective inhibition of NAALADase, which converts NAAG to glutamate, reduces ischemic brain injury. Nat. Med. 5, 1396-1402.
41. Spooren W. P., Gasparini F., van der Putten H., Koller M., Nakanishi S. and Kuhn R. (2000) Lack of effect of LY314582 (a group 2 metabotropic glutamate receptor agonist) on phencyclidine-induced locomotor activity in metabotropic glutamate receptor 2 knockout mice. Eur. J. Pharmacol. 397, R1-R2.
42. Swanson C. J., Perry K. W. and Schoepp D. D. (2004) The mGlu2/3 receptor agonist, LY35740, blocks immobilization-induced increases in noradrenaline and dopamine release in the rat medial prefrontal cortex. J. Neurochem. 88, 194-202.
43. Tamaru Y., Nomura S., Mizuno N. and Shigemoto R. (2001) Distribution of metabotropic glutamate receptor mGluR3 in the mouse CNS: differential location relative to pre- and postsynaptic sites. Neuroscience 106, 481-503.
44. Tsai G. and Coyle J. T. (2002) Glutamatergic mechanisms in schizophrenia. Annu. Rev. Pharmacol. Toxicol. 42, 165-179.
45. Winter J. C., Eckler J. R. and Rabin R. A. (2003) Serotonergicv/glutamatergic interactions: the effects of mGlu (2/3) receptor ligands in rats trained with LSD and PCP as discriminative stimuli. Psychopharmacology November 4 [Epub ahead of print].
46. Wroblewska B., Wroblewski J. T., Pshenichkin S., Surin A., Sullivan S. E. and Neale J. H. (1997) N-Acetylaspartylglutamate selectively activates mGluR3 receptors in transfected cells. J. Neurochem. 69, 174-181.
47. Xi Z.-X., Baker D. A., Shen H., Carson D. S. and Kalivas P. W. (2002) Group II metabotropic glutamate receptors modulate extracellular glutamate in the nucleus accumbens. JPET 300, 162-171.
48. Yamamoto T., Natsuko N.-T. and Yoshihiko S. (2001) Spinal N-acetyl-[alpha]-linked acidic dipeptidase (NAALADase) inhibition attenuates mechanical allodynia induced by paw carrageenan injection in the rat. Brain Res. 909, 138-144.
49. Zhang W., Slusher B., Murakawa Y., Wozniak K. M., Tsukamoto T., Jackson P. F. and Sima A. A. (2002) GCPII (NAALADase) inhibition prevents long-term diabetic neuropathy in type 1 diabetic BB/Wor rats. J. Neurol. Sci. 194, 21-28.
50. Zhao J., Ramadan E., Cappiello M., Wroblewska B., Bzdega T. and Neale J. H. (2001) NAAG inhibits KCl-induced. Eur. J. Neurosci. 13, 340-346.